Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.
Edoardo Francini, Daniel Yick Chin Heng(University of Calgary), Nimira Alimohamed(University of Calgary), Jesús García‐Foncillas(Hospital Universitario Fundación Jiménez Díaz), Alan H. Bryce(Mayo Clinic Hospital), Richard M. Lee‐Ying(Alberta Health Services), Roberto Petrioli(Azienda Ospedaliera Universitaria Senese), Francesca Crivelli(Ospedale degli Infermi), Lauren C. Harshman(Dana-Farber Cancer Institute), Miguel González-Vélez(Mayo Clinic Hospital), Guido Francini(University of Siena), Grace Shaw(Dana-Farber Cancer Institute), Carmelo Bengala(Ospedale Misericordia - Grosseto), Pietro Rosellini(University of Siena), Jaime Rubio(Hospital Universitario Fundación Jiménez Díaz), Irene Moreno Candilejo, Francesca Montagnani(University of Siena), Li Zhang(Fourth Hospital of Changsha), Nuzzo Pier Vitale(Dana-Farber Cancer Institute), Christopher J. Sweeney(The University of Adelaide)
Cited by 0
Related Papers
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k